To many, the recent FDA approval of a combination of chemotherapy and concurrent immunotherapy for the vast majority of patients with advanced (metastatic) non-squamous non-small cell lung cancer (NSCLC) probably seems like a great idea.
Dr. Jonathan Goldman joins GRACE to explain why carboplatin, pemetrexed and pembrolizumab has become his new go-to regimen for first-line non-squamous NSCLC treatment.
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are converging...
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are converging...
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
Ketki Patel, a Patient Financial Advocate in Seattle recently offered suggestions and helpful information for financial navigation during your cancer...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.